Point72 (Difc) LTD Eli Lilly & CO Call Options Transaction History

Point72 (Difc) LTD

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$772.14 - $960.02 $6.1 Million - $7.58 Million	-7,900 Reduced 82.29%	1,700 $1.51 Billion
Q2 2024 Aug 14, 2024	SELL	$724.87 - $909.04 $4.71 Million - $5.91 Million	-6,500 Reduced 40.37%	9,600 $8.69 Billion
Q1 2024 May 15, 2024	BUY	$592.2 - $792.28 $9.53 Million - $12.8 Million	16,100 New	16,100 $12.5 Billion

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $749B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Point72 (Difc) LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 (Difc) LTD with notifications on news.